Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

BACKGROUND: We report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Both of these drugs are effectors in the mitogen-activated protein kinase (...

Descripción completa

Detalles Bibliográficos
Autores principales: Draganova, Dafina, Kerger, Joseph, Caspers, Laure, Willermain, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460117/
https://www.ncbi.nlm.nih.gov/pubmed/26078801
http://dx.doi.org/10.1186/s12348-015-0049-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460117/
https://www.ncbi.nlm.nih.gov/pubmed/26078801
http://dx.doi.org/10.1186/s12348-015-0049-9

Ejemplares similares